Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ReGen Challenges FDA Report's Facts And Motivation

This article was originally published in The Gray Sheet

Executive Summary

The details of FDA's recent review of ReGen Biologics' Menaflex knee repair device clearance stunned many device industry insiders - but none so much as the company itself
Advertisement

Related Content

FDA Questions Data Supporting ReGen's Menaflex Ahead Of 510(k) Re-Review
FDA Questions Data Supporting ReGen's Menaflex Ahead Of 510(k) Re-Review
FDA To Implement Recommendations From 510(k) Task Force Within Months
FDA To Implement Recommendations From 510(k) Task Force Within Months
Internal FDA Menaflex Investigation Finds Serious Process Deviations
Internal FDA Menaflex Investigation Finds Serious Process Deviations
Do-Over? FDA Orders Look-Back At Knee Device 510(k) Review Process
Device Center Discord: 510(k) Review Process Is Flash Point At CDRH

Topics

Advertisement
UsernamePublicRestriction

Register

MT028003

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel